A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-05 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
The body of the royal angelfish is moderately elongate and is very compressed. The preorbital bone is convex and has no strong spines. There is 1 prominent spine at an angle at the preopercal. The ventral edge of the interopercle is smooth. The eyes are moderately small along with the mouth that is terminal. The mouth is also protractile. They have a maximum length of 25.0 cm (9.8 in). They have a total of 14 dorsal spines, and 17–19 soft dorsal rays. They have 3 anal spines and 17–19 anal soft rays. They also have 16–17 pectoral fin rays. Their caudal fin is rounded. The precise coloration of this fish can vary as regional differences can occur, most notably in populations from the Indian Ocean, Red Sea, and South Pacific Ocean. A commonality, however, is a body edged in narrow blue-white and orange stripes that are narrow and angle backward. The posterior portion of dorsal fin is black or blue with close-set blue dots, and the posterior portion of anal fin has alternating yellow and blue bands running parallel to body contour. The caudal fin is yellow. Juveniles are colored with a large dark spot on basal portion of the soft dorsal fin. They have been reported of living 15 years. Recent research indicates that the Pygoplites comprises two morphs, with the variants potentially hybridizing at Christmas Island.
=== Long term === If a person with type 1 diabetes who has diabulimia has the disease for more than a short time—usually due to alternating phases during which insulin is injected properly and relapses during which they have diabulimia—then the following longer-term symptoms can be expected:
In conjunction with the construction of Einstein's first building, New York City built a 1,349-bed, $37.5 million hospital adjacent to the school, now known as the Jacobi Medical Center. Belkin and New York City Mayor Vincent Impellitteri agreed to permit its use as Einstein's teaching hospital. Jacobi is a member of NYC Health + Hospitals, the largest municipal health system in the United States. It serves as both the regional snakebite center and hyperbaric center for the New York tri-state area.
Sources: en.wikipedia.org
=== Pregnancy === Antidepressant exposure (including paroxetine) is associated with shorter duration of pregnancy (by three days), increased risk of preterm delivery (by 55%), lower birth weight (by 75 g or 2.6 oz), and lower Apgar scores (by <0.4 points). The American College of Obstetricians and Gynecologists recommends that for pregnant women and women planning to become pregnant, paroxetine "be avoided, if possible", as it may be associated with increased risk of birth defects. Babies born to women who used paroxetine during the first trimester have an increased risk of cardiovascular malformations, primarily ventricular and atrial septal defects. Unless the benefits of paroxetine justify continuing treatment, consideration should be given to stopping or switching to another antidepressant. Paroxetine use during pregnancy is associated with about 1.5– to 1.7-fold increase in congenital birth defects, in particular, heart defects, cleft lip and palate, clubbed feet, or any birth defects.
==== European Union ==== In February 2016, orphan designation (EU/3/16/1615) was granted by the European Commission to Gilead Sciences International Ltd, United Kingdom, for remdesivir for the treatment of Ebola virus disease. In April 2020, the European Medicines Agency (EMA) provided recommendations on compassionate use of remdesivir for COVID‑19 in the EU. In May 2020, the Committee for Medicinal Products for Human Use (CHMP) of the EMA recommended expanding the compassionate use of remdesivir to those not on mechanical ventilation. In addition to those undergoing invasive mechanical ventilation, the compassionate use recommendations cover the treatment of hospitalized individuals requiring supplemental oxygen, non-invasive ventilation, high-flow oxygen devices or ECMO (extracorporeal membrane oxygenation). The updated recommendations were based on preliminary results from the NIAID-ACTT study, which suggested a beneficial effect of remdesivir in the treatment of hospitalized individuals with severe COVID‑19. In addition, a treatment duration of five days was introduced alongside the longer ten-day course, based on preliminary results from another study (GS-US-540-5773) suggesting that for those not requiring mechanical ventilation or ECMO, the treatment course may be shortened from ten to five days without any loss of efficacy. Individuals who receive a five-day treatment course but do not show clinical improvement will be eligible to continue receiving remdesivir for an additional five days.
As of 2025, the artificial intelligence (AI) market in the United Kingdom is worth over £21 billion, and is expected to exceed £1 trillion by 2035. It is the world's third-largest AI market and consistently ranked 3rd in private AI funding between 2013 and 2024, both behind the United States and China. The country ranked fifth globally in a 2024 report on AI development by Stanford University. In the first (2024) edition of GIRAI, the United Kingdom was ranked 4th out of 138 countries assessed and in the second (2026) edition, the country rank fell to 7th out of 135 countries. The UK AI market is valued at over £21 billion in 2025 and projected to exceed £1 trillion by 2035. The UK's prominence is rooted in a strong historical foundation, beginning with Alan Turing's theoretical work in the 1930s and 1940s, and the establishment of early AI research centres in the 1960s, such as those at the University of Edinburgh. Despite periods of reduced funding known as "AI winters", modern UK AI research has seen significant breakthroughs, most notably through London-based DeepMind's achievements in deep reinforcement learning and protein structure prediction. The UK AI sector has experienced rapid growth. The number of AI companies increased by 85% between 2022 and 2024, reaching 5,862 firms. In 2024, the sector generated an estimated £23.9 billion in revenue and £11.8 billion in Gross Value Added (GVA), employing over 86,000 people.
Oxandrolone was recommended as an adjunctive therapy, alongside insulin, metformin, and closely monitored propranolol, in severe burn patients, for metabolic and nutritional support. Oxandrolone improves both short-term and long-term outcomes in people recovering from severe burns and was well-established as a safe treatment for this indication. One of the underlying mechanisms in burn management is that oxandrolone helps reduce hypermetabolic response, which is characterized by increased energy expenditure, elevated stress hormones levels such as cortisol, insulin resistance, muscle wasting, and impaired wound healing; this response is reduced by improving whole-body nitrogen balance as well as preserving lean body mass during recovery. As of 2019, oxandrolone was prescribed off-label for the development of girls with Turner syndrome, and counteract wasting of diverse origin. As of 2012, oxandrolone was used in the treatment of idiopathic short stature, anemia, hereditary angioedema, hypogonadism and alcoholic hepatitis. Medical research established the effectiveness of oxandrolone in aiding the development of girls with Turner syndrome. Although oxandrolone had long been used to accelerate growth in children with idiopathic short stature, it is unlikely to increase adult height, and in some cases may even decrease it; as such, as of 2015, oxandrolone has largely been replaced by growth hormone for this use.
Sources: en.wikipedia.org
=== Eating disorders === The American Dietetic Association discussed that vegetarian diets may be more common among adolescents with eating disorders, indicating that vegetarian diets do not cause eating disorders, but rather "vegetarian diets may be selected to camouflage an existing eating disorder".
== Further reading == "Plates vs. Plumes: A Geological Controversy". Wiley-Blackwell. October 2010. Boschi, L.; Becker, T.W.; Steinberger, B. (2007). "Mantle plumes: Dynamic models and seismic images" (PDF). Geochemistry, Geophysics, Geosystems. 8 (Q10006): Q10006. Bibcode:2007GGG.....810006B. doi:10.1029/2007GC001733. ISSN 1525-2027. Clouard, Valérie; Gerbault, Muriel (2007). "Break-up spots: Could the Pacific open as a consequence of plate kinematics?" (PDF). Earth and Planetary Science Letters. 265 (1–2): 195. Bibcode:2008E&PSL.265..195C. doi:10.1016/j.epsl.2007.10.013. "Towards A Better Understanding Of Hot Spot Volcanism". ScienceDaily. 4 February 2008.
=== Cyclic peptide binders Screening === Cyclic peptides can be successfully displayed on bacterial cell surface. By DNA randomization millions of cyclic peptides displayed on cell surface can be screened against a protein target using high-throughput FACS.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.